drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00414 | DB00687 | 590 | 870 | [
"DDInter16",
"DDInter747"
] | Acetohexamide | Fludrocortisone | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
590,
24,
870
]
],
[
[
590,
24,
1220
],
[
1220,
40,
870
]
],
[
[
590,
24,
1561
],
[
1561,
24,
870
]
],
[
[
590,
63,
989
],
[
989,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone may cause a moderate i... |
DB01142 | DB11642 | 1,264 | 938 | [
"DDInter593",
"DDInter1480"
] | Doxepin | Pitolisant | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1264,
24,
938
]
],
[
[
1264,
62,
112
],
[
112,
23,
938
]
],
[
[
1264,
24,
760
],
[
760,
24,
938
]
],
[
[
1264,
63,
600
],
[
600,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"... | Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat... |
DB01242 | DB01268 | 1,237 | 1,151 | [
"DDInter410",
"DDInter1731"
] | Clomipramine | Sunitinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1237,
24,
1151
]
],
[
[
1237,
63,
1311
],
[
1311,
1,
1151
]
],
[
[
1237,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
1237,
21,
29269
],
[
292... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Clomipramine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Clomipramine (Compound) causes Menopausal symptoms (Side E... |
DB11248 | DB11834 | 1,193 | 1,303 | [
"DDInter1965",
"DDInter849"
] | Zinc gluconate | Guselkumab | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wit... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Minor | 0 | [
[
[
1193,
23,
1303
]
],
[
[
1193,
62,
58
],
[
58,
24,
1303
]
],
[
[
1193,
23,
270
],
[
270,
63,
1303
]
],
[
[
1193,
62,
375
],
[
375,
... | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Guselkumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
[... | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocr... |
DB00357 | DB00701 | 1,051 | 1,091 | [
"DDInter71",
"DDInter90"
] | Aminoglutethimide | Amprenavir | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Amprenavir is a protease inhibitor used to treat HIV infection. | Moderate | 1 | [
[
[
1051,
24,
1091
]
],
[
[
1051,
24,
34
],
[
34,
1,
1091
]
],
[
[
1051,
6,
10215
],
[
10215,
45,
1091
]
],
[
[
1051,
21,
28996
],
[
28996... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Aminoglutethimide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Amprenavir (Compound)
Aminoglutethimide (Compound) causes Musculos... |
DB00106 | DB00738 | 618 | 485 | [
"DDInter4",
"DDInter1420"
] | Abarelix | Pentamidine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
618,
24,
485
]
],
[
[
618,
23,
1247
],
[
1247,
62,
485
]
],
[
[
618,
24,
971
],
[
971,
63,
485
]
],
[
[
618,
24,
1516
],
[
1516,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pentamidine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and... |
DB00619 | DB14443 | 1,419 | 987 | [
"DDInter909",
"DDInter1931"
] | Imatinib | Vibrio cholerae CVD 103-HgR strain live antigen | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1419,
24,
987
]
],
[
[
1419,
63,
141
],
[
141,
24,
987
]
],
[
[
1419,
35,
1468
],
[
1468,
24,
987
]
],
[
[
1419,
24,
1220
],
[
1220,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a... |
DB01267 | DB06589 | 519 | 1,250 | [
"DDInter1381",
"DDInter1400"
] | Paliperidone | Pazopanib | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
519,
24,
1250
]
],
[
[
519,
6,
12523
],
[
12523,
45,
1250
]
],
[
[
519,
21,
29203
],
[
29203,
60,
1250
]
],
[
[
519,
62,
112
],
[
112,... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Paliperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Paliperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pazopanib (Compound)
Paliperidone (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Paliperidone may cause a minor interaction that can li... |
DB00909 | DB01259 | 306 | 392 | [
"DDInter1971",
"DDInter1024"
] | Zonisamide | Lapatinib | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
306,
24,
392
]
],
[
[
306,
6,
8374
],
[
8374,
45,
392
]
],
[
[
306,
21,
28852
],
[
28852,
60,
392
]
],
[
[
306,
24,
918
],
[
918,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Zonisamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zonisamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Zonisamide (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bi... |
DB00990 | DB01045 | 1,547 | 463 | [
"DDInter705",
"DDInter1590"
] | Exemestane | Rifampicin | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
1547,
24,
463
]
],
[
[
1547,
63,
690
],
[
690,
40,
463
]
],
[
[
1547,
6,
8374
],
[
8374,
45,
463
]
],
[
[
1547,
63,
1101
],
[
1101,
... | [
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
... | Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Exemestane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifampicin (Compound)
Exemestane may cause a moderate interaction that could exacerbate di... |
DB00500 | DB13074 | 24 | 877 | [
"DDInter1831",
"DDInter1110"
] | Tolmetin | Macimorelin | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
24,
24,
877
]
],
[
[
24,
24,
1479
],
[
1479,
24,
877
]
],
[
[
24,
40,
1263
],
[
1263,
24,
877
]
],
[
[
24,
63,
251
],
[
251,
24,... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Tolmetin (Compound) resembles Bromfenac (Compound) and Bromfenac may cause a moderate interac... |
DB08880 | DB15965 | 1,510 | 1,330 | [
"DDInter1771",
"DDInter1270"
] | Teriflunomide | Naxitamab | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Major | 2 | [
[
[
1510,
25,
1330
]
],
[
[
1510,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
1510,
64,
1532
],
[
1532,
24,
1330
]
],
[
[
1510,
63,
10
],
[
10,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zin... | Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Teriflunomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide m... |
DB11730 | DB12887 | 351 | 1,598 | [
"DDInter1588",
"DDInter1750"
] | Ribociclib | Tazemetostat | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Major | 2 | [
[
[
351,
25,
1598
]
],
[
[
351,
64,
594
],
[
594,
24,
1598
]
],
[
[
351,
63,
310
],
[
310,
24,
1598
]
],
[
[
351,
24,
738
],
[
738,
... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} m... | Ribociclib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may caus... |
DB01030 | DB09073 | 869 | 951 | [
"DDInter1835",
"DDInter1379"
] | Topotecan | Palbociclib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
869,
24,
951
]
],
[
[
869,
24,
496
],
[
496,
63,
951
]
],
[
[
869,
24,
259
],
[
259,
24,
951
]
],
[
[
869,
63,
134
],
[
134,
24,... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Rilo... |
DB01097 | DB02701 | 1,377 | 1,632 | [
"DDInter1033",
"DDInter1289"
] | Leflunomide | Nicotinamide | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | Major | 2 | [
[
[
1377,
25,
1632
]
],
[
[
1377,
64,
1236
],
[
1236,
23,
1632
]
],
[
[
1377,
63,
1144
],
[
1144,
24,
1632
]
],
[
[
1377,
25,
384
],
[
384... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nicotinamide"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
... | Leflunomide may lead to a major life threatening interaction when taken with Carbamazepine and Carbamazepine may cause a minor interaction that can limit clinical effects when taken with Nicotinamide
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide ... |
DB00682 | DB01330 | 126 | 1,402 | [
"DDInter1951",
"DDInter324"
] | Warfarin | Cefotetan | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. | Moderate | 1 | [
[
[
126,
24,
1402
]
],
[
[
126,
24,
1124
],
[
1124,
1,
1402
]
],
[
[
126,
24,
1558
],
[
1558,
40,
1402
]
],
[
[
126,
63,
277
],
[
277,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotetan"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole and Cefamandole (Compound) resembles Cefotetan (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin and Cefoxitin (Compound) resembles Cefotetan (Compound)
Warfar... |
DB00994 | DB01203 | 361 | 699 | [
"DDInter1277",
"DDInter1255"
] | Neomycin | Nadolol | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Minor | 0 | [
[
[
361,
23,
699
]
],
[
[
361,
21,
28722
],
[
28722,
60,
699
]
],
[
[
361,
35,
416
],
[
416,
23,
699
]
],
[
[
361,
25,
1552
],
[
1552,
... | [
[
[
"Neomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
]
],
[
[
"Neomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Comp... | Neomycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Nadolol (Compound)
Neomycin (Compound) resembles Kanamycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a minor interaction that can limit cl... |
DB00445 | DB09291 | 322 | 741 | [
"DDInter655",
"DDInter1615"
] | Epirubicin | Rolapitant | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
322,
24,
741
]
],
[
[
322,
24,
479
],
[
479,
23,
741
]
],
[
[
322,
24,
159
],
[
159,
63,
741
]
],
[
[
322,
25,
924
],
[
924,
24,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotre... |
DB00585 | DB01067 | 1,127 | 959 | [
"DDInter1309",
"DDInter826"
] | Nizatidine | Glipizide | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1127,
24,
959
]
],
[
[
1127,
63,
245
],
[
245,
40,
959
]
],
[
[
1127,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1127,
7,
2652
],
[
2652,
... | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB00401 | DB01069 | 84 | 401 | [
"DDInter1298",
"DDInter1533"
] | Nisoldipine | Promethazine | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
84,
24,
401
]
],
[
[
84,
24,
820
],
[
820,
63,
401
]
],
[
[
84,
24,
104
],
[
104,
24,
401
]
],
[
[
84,
6,
4973
],
[
4973,
45,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine an... |
DB00374 | DB01144 | 1,061 | 1,326 | [
"DDInter1852",
"DDInter540"
] | Treprostinil | Diclofenamide | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
1061,
24,
1326
]
],
[
[
1061,
24,
504
],
[
504,
1,
1326
]
],
[
[
1061,
24,
359
],
[
359,
40,
1326
]
],
[
[
1061,
6,
6017
],
[
6017,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound)... |
DB00682 | DB01181 | 126 | 1,532 | [
"DDInter1951",
"DDInter906"
] | Warfarin | Ifosfamide | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
126,
24,
1532
]
],
[
[
126,
6,
3486
],
[
3486,
45,
1532
]
],
[
[
126,
25,
1299
],
[
1299,
23,
1532
]
],
[
[
126,
35,
307
],
[
307,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Warfarin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ifosfamide (Compound)
Warfarin may lead to a major life threatening interaction when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Warfarin (Compound) resembles Mod... |
DB01075 | DB12161 | 1,376 | 730 | [
"DDInter569",
"DDInter512"
] | Diphenhydramine | Deutetrabenazine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
1376,
24,
730
]
],
[
[
1376,
74,
100
],
[
100,
24,
730
]
],
[
[
1376,
35,
1264
],
[
1264,
24,
730
]
],
[
[
1376,
63,
1219
],
[
1219,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate disea... | Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Diphenhydramine (Compou... |
DB00631 | DB11652 | 372 | 1,155 | [
"DDInter405",
"DDInter1891"
] | Clofarabine | Tucatinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
372,
24,
1155
]
],
[
[
372,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
372,
24,
609
],
[
609,
24,
1155
]
],
[
[
372,
63,
522
],
[
522,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cla... |
DB00631 | DB05679 | 372 | 1,683 | [
"DDInter405",
"DDInter1907"
] | Clofarabine | Ustekinumab | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
372,
24,
1683
]
],
[
[
372,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
372,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
372,
63,
305
],
[
305,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib ... |
DB00278 | DB00963 | 291 | 1,263 | [
"DDInter117",
"DDInter241"
] | Argatroban | Bromfenac | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Moderate | 1 | [
[
[
291,
24,
1263
]
],
[
[
291,
24,
935
],
[
935,
40,
1263
]
],
[
[
291,
24,
1512
],
[
1512,
24,
1263
]
],
[
[
291,
21,
28645
],
[
28645,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could ... |
DB00681 | DB01250 | 1,287 | 712 | [
"DDInter85",
"DDInter1334"
] | Amphotericin B | Olsalazine | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
1287,
24,
712
]
],
[
[
1287,
24,
50
],
[
50,
40,
712
]
],
[
[
1287,
24,
416
],
[
416,
24,
712
]
],
[
[
1287,
64,
789
],
[
789,
2... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interactio... |
DB00312 | DB11718 | 1,023 | 927 | [
"DDInter1423",
"DDInter640"
] | Pentobarbital | Encorafenib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1023,
24,
927
]
],
[
[
1023,
24,
112
],
[
112,
23,
927
]
],
[
[
1023,
1,
536
],
[
536,
24,
927
]
],
[
[
1023,
24,
1491
],
[
1491,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Pentobarbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interac... |
DB01075 | DB01186 | 1,376 | 107 | [
"DDInter569",
"DDInter1430"
] | Diphenhydramine | Pergolide | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
1376,
24,
107
]
],
[
[
1376,
6,
12523
],
[
12523,
45,
107
]
],
[
[
1376,
10,
11558
],
[
11558,
49,
107
]
],
[
[
1376,
21,
28757
],
[
2... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Co... | Diphenhydramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pergolide (Compound)
Diphenhydramine (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is palliated by Pergolide (Compound)
Diphenhydramine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect... |
DB01144 | DB01362 | 1,326 | 497 | [
"DDInter540",
"DDInter960"
] | Diclofenamide | Iohexol | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
1326,
24,
497
]
],
[
[
1326,
24,
258
],
[
258,
40,
497
]
],
[
[
1326,
21,
28921
],
[
28921,
60,
497
]
],
[
[
1326,
1,
674
],
[
674,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Diclofenamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Iohexol (Compound)
Diclofenamide (Compound) resembles Trichlormet... |
DB00048 | DB08816 | 1,595 | 578 | [
"DDInter435",
"DDInter1802"
] | Collagenase clostridium histolyticum | Ticagrelor | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1595,
24,
578
]
],
[
[
1595,
63,
1578
],
[
1578,
24,
578
]
],
[
[
1595,
24,
1347
],
[
1347,
24,
578
]
],
[
[
1595,
24,
840
],
[
840,
... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerb... |
DB00011 | DB00242 | 1,451 | 1,064 | [
"DDInter944",
"DDInter392"
] | Interferon alfa-n1 | Cladribine | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
1451,
25,
1064
]
],
[
[
1451,
24,
372
],
[
372,
64,
1064
]
],
[
[
1451,
24,
869
],
[
869,
63,
1064
]
],
[
[
1451,
24,
1253
],
[
1253,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topo... |
DB00748 | DB14575 | 662 | 733 | [
"DDInter297",
"DDInter674"
] | Carbinoxamine | Eslicarbazepine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
662,
24,
733
]
],
[
[
662,
24,
1264
],
[
1264,
24,
733
]
],
[
[
662,
35,
272
],
[
272,
24,
733
]
],
[
[
662,
63,
1614
],
[
1614,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Carbinoxamine (Compound) resembles Chlorpheniramine (Compound) and Carbinoxamine may cause a moderate interact... |
DB01097 | DB11952 | 1,377 | 800 | [
"DDInter1033",
"DDInter612"
] | Leflunomide | Duvelisib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
1377,
25,
800
]
],
[
[
1377,
25,
310
],
[
310,
24,
800
]
],
[
[
1377,
64,
467
],
[
467,
24,
800
]
],
[
[
1377,
25,
1476
],
[
1476,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u... | Leflunomide may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Leflunomide may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate... |
DB00440 | DB00761 | 1,548 | 1,621 | [
"DDInter1874",
"DDInter1497"
] | Trimethoprim | Potassium chloride | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Major | 2 | [
[
[
1548,
25,
1621
]
],
[
[
1548,
21,
28809
],
[
28809,
60,
1621
]
],
[
[
1548,
21,
28809
],
[
28809,
60,
803
],
[
803,
1,
1621
]
],
[
[
1... | [
[
[
"Trimethoprim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Trimethoprim",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused ... | Trimethoprim (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Potassium chloride (Compound)
Trimethoprim (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Calcium chloride (Compound) and Calcium chloride (Compound) resembles Potassium chloride (Compound... |
DB04868 | DB12141 | 478 | 971 | [
"DDInter1293",
"DDInter817"
] | Nilotinib | Gilteritinib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
478,
25,
971
]
],
[
[
478,
23,
1135
],
[
1135,
23,
971
]
],
[
[
478,
62,
1247
],
[
1247,
23,
971
]
],
[
[
478,
23,
466
],
[
466,
... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamet... |
DB00476 | DB01501 | 109 | 1,118 | [
"DDInter608",
"DDInter549"
] | Duloxetine | Difenoxin | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | Moderate | 1 | [
[
[
109,
24,
1118
]
],
[
[
109,
24,
1688
],
[
1688,
40,
1118
]
],
[
[
109,
25,
506
],
[
506,
24,
1118
]
],
[
[
109,
24,
1614
],
[
1614,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Duloxetine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that cou... |
DB01220 | DB04908 | 1,088 | 1,671 | [
"DDInter1593",
"DDInter741"
] | Rifaximin | Flibanserin | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduc... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
1088,
24,
1671
]
],
[
[
1088,
24,
741
],
[
741,
63,
1671
]
],
[
[
1088,
24,
478
],
[
478,
24,
1671
]
],
[
[
1088,
24,
913
],
[
913,
... | [
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotini... |
DB00470 | DB06691 | 530 | 849 | [
"DDInter601",
"DDInter1155"
] | Dronabinol | Mepyramine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
530,
24,
849
]
],
[
[
530,
63,
1594
],
[
1594,
24,
849
]
],
[
[
530,
24,
272
],
[
272,
24,
849
]
],
[
[
530,
24,
407
],
[
407,
6... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and ... |
DB00357 | DB09330 | 1,051 | 985 | [
"DDInter71",
"DDInter1352"
] | Aminoglutethimide | Osimertinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1051,
24,
985
]
],
[
[
1051,
62,
168
],
[
168,
23,
985
]
],
[
[
1051,
24,
1478
],
[
1478,
24,
985
]
],
[
[
1051,
24,
1598
],
[
1598,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
... | Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor ... |
DB01177 | DB01591 | 77 | 667 | [
"DDInter904",
"DDInter1696"
] | Idarubicin | Solifenacin | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
77,
24,
667
]
],
[
[
77,
21,
28743
],
[
28743,
60,
667
]
],
[
[
77,
62,
112
],
[
112,
23,
667
]
],
[
[
77,
24,
774
],
[
774,
63,... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Idarubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Atrial fibrillation"
],
[
"Atrial fibrillation",
"{u} ... | Idarubicin (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects ... |
DB00307 | DB00834 | 1,101 | 932 | [
"DDInter202",
"DDInter1215"
] | Bexarotene | Mifepristone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Minor | 0 | [
[
[
1101,
23,
932
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
932
]
],
[
[
1101,
21,
29152
],
[
29152,
60,
932
]
],
[
[
1101,
24,
1499
],
[
1499... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mifepristone"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mifepristone (Compound)
Bexarotene (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Mifepristone (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Nalde... |
DB00211 | DB01105 | 1,290 | 222 | [
"DDInter1213",
"DDInter1665"
] | Midodrine | Sibutramine | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1290,
24,
222
]
],
[
[
1290,
21,
28698
],
[
28698,
60,
222
]
],
[
[
1290,
23,
752
],
[
752,
23,
222
]
],
[
[
1290,
24,
659
],
[
659,
... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Midodrine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused ... | Midodrine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sibutramine (Compound)
Midodrine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Mi... |
DB00515 | DB01099 | 589 | 1,272 | [
"DDInter387",
"DDInter744"
] | Cisplatin | Flucytosine | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
589,
24,
1272
]
],
[
[
589,
21,
29209
],
[
29209,
60,
1272
]
],
[
[
589,
24,
1224
],
[
1224,
23,
1272
]
],
[
[
589,
24,
1448
],
[
1448... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused ... | Cisplatin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Flucytosine (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine may cause a minor interaction that can limit clinical effects when taken with Flucytosine
... |
DB01072 | DB06723 | 915 | 115 | [
"DDInter129",
"DDInter58"
] | Atazanavir | Aluminum hydroxide | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
915,
24,
115
]
],
[
[
915,
21,
28643
],
[
28643,
60,
115
]
],
[
[
915,
63,
870
],
[
870,
23,
115
]
],
[
[
915,
64,
175
],
[
175,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Atazanavir",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect)... | Atazanavir (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when ta... |
DB01166 | DB11978 | 477 | 124 | [
"DDInter379",
"DDInter822"
] | Cilostazol | Glasdegib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
477,
24,
124
]
],
[
[
477,
62,
1247
],
[
1247,
23,
124
]
],
[
[
477,
24,
1079
],
[
1079,
24,
124
]
],
[
[
477,
24,
1032
],
[
1032,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and... |
DB09570 | DB10343 | 1,480 | 962 | [
"DDInter1002",
"DDInter160"
] | Ixazomib | Bacillus calmette-guerin substrain tice live antigen | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1480,
25,
962
]
],
[
[
1480,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1480,
24,
270
],
[
270,
64,
962
]
],
[
[
1480,
63,
663
],
[
663,
... | [
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
... | Ixazomib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab a... |
DB05294 | DB11113 | 1,069 | 657 | [
"DDInter1917",
"DDInter307"
] | Vandetanib | Castor oil | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1069,
24,
657
]
],
[
[
1069,
25,
1079
],
[
1079,
24,
657
]
],
[
[
1069,
25,
927
],
[
927,
63,
657
]
],
[
[
1069,
64,
540
],
[
540,
... | [
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
],
[
"Telavancin... | Vandetanib may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Vandetanib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate in... |
DB06372 | DB12498 | 259 | 76 | [
"DDInter1594",
"DDInter1238"
] | Rilonacept | Mogamulizumab | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Moderate | 1 | [
[
[
259,
24,
76
]
],
[
[
259,
62,
1461
],
[
1461,
23,
76
]
],
[
[
259,
23,
1193
],
[
1193,
23,
76
]
],
[
[
259,
63,
1531
],
[
1531,
... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gl... |
DB05578 | DB06700 | 330 | 643 | [
"DDInter1566",
"DDInter511"
] | Ramucirumab | Desvenlafaxine | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
330,
24,
643
]
],
[
[
330,
63,
1100
],
[
1100,
1,
643
]
],
[
[
330,
25,
292
],
[
292,
63,
643
]
],
[
[
330,
76,
1274
],
[
1274,
... | [
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
... | Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Ramucirumab may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exac... |
DB00782 | DB01043 | 1,123 | 108 | [
"DDInter1535",
"DDInter1146"
] | Propantheline | Memantine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Moderate | 1 | [
[
[
1123,
24,
108
]
],
[
[
1123,
21,
28691
],
[
28691,
60,
108
]
],
[
[
1123,
24,
1117
],
[
1117,
62,
108
]
],
[
[
1123,
24,
1264
],
[
126... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Memantine"
]
],
[
[
"Propantheline",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) ... | Propantheline (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Memantine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects wh... |
DB00014 | DB01044 | 521 | 246 | [
"DDInter839",
"DDInter809"
] | Goserelin | Gatifloxacin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
521,
25,
246
]
],
[
[
521,
24,
739
],
[
739,
1,
246
]
],
[
[
521,
25,
1176
],
[
1176,
1,
246
]
],
[
[
521,
25,
945
],
[
945,
40,... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomeflox... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Goserelin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Goser... |
DB01115 | DB15091 | 336 | 676 | [
"DDInter1291",
"DDInter1901"
] | Nifedipine | Upadacitinib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
336,
24,
676
]
],
[
[
336,
24,
283
],
[
283,
24,
676
]
],
[
[
336,
63,
600
],
[
600,
24,
676
]
],
[
[
336,
63,
1184
],
[
1184,
2... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flu... |
DB05239 | DB06448 | 866 | 171 | [
"DDInter425",
"DDInter1087"
] | Cobimetinib | Lonafarnib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Major | 2 | [
[
[
866,
25,
171
]
],
[
[
866,
63,
888
],
[
888,
24,
171
]
],
[
[
866,
24,
850
],
[
850,
63,
171
]
],
[
[
866,
64,
1064
],
[
1064,
2... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin a... |
DB01206 | DB06643 | 37 | 1,136 | [
"DDInter1086",
"DDInter500"
] | Lomustine | Denosumab | An alkylating agent of value against both hematologic malignancies and solid tumors. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
37,
24,
1136
]
],
[
[
37,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
37,
74,
552
],
[
552,
24,
1136
]
],
[
[
37,
64,
1377
],
[
1377,
... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Lomustine (Compound) resembles Carmustine (Compound) and Lomustine may cause a moderate interaction that could e... |
DB01219 | DB09122 | 716 | 1,613 | [
"DDInter473",
"DDInter1409"
] | Dantrolene | Peginterferon beta-1a | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
716,
24,
1613
]
],
[
[
716,
63,
267
],
[
267,
24,
1613
]
],
[
[
716,
24,
850
],
[
850,
24,
1613
]
],
[
[
716,
64,
1377
],
[
1377,
... | [
[
[
"Dantrolene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Dantrolene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Dantrolene may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Dantrolene may cause a moderate interaction that could exacerbate diseases when taken with Brentuxima... |
DB01035 | DB06616 | 1,401 | 594 | [
"DDInter1524",
"DDInter224"
] | Procainamide | Bosutinib | A derivative of procaine with less CNS action. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
1401,
25,
594
]
],
[
[
1401,
21,
29231
],
[
29231,
60,
594
]
],
[
[
1401,
62,
112
],
[
112,
23,
594
]
],
[
[
1401,
63,
1559
],
[
1559,... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Procainamide",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is ca... | Procainamide (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when... |
DB00975 | DB08901 | 1,317 | 1,468 | [
"DDInter573",
"DDInter1492"
] | Dipyridamole | Ponatinib | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1317,
25,
1468
]
],
[
[
1317,
6,
4973
],
[
4973,
45,
1468
]
],
[
[
1317,
21,
29271
],
[
29271,
60,
1468
]
],
[
[
1317,
63,
1230
],
[
1... | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Dipyridamole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ponati... | Dipyridamole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Dipyridamole (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Cita... |
DB00321 | DB01233 | 21 | 1,311 | [
"DDInter78",
"DDInter1197"
] | Amitriptyline | Metoclopramide | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
21,
24,
1311
]
],
[
[
21,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
21,
25,
1425
],
[
1425,
40,
1311
]
],
[
[
21,
6,
5289
],
[
5289,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Amitriptyline may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Metoclopramide (Compound)
Amitr... |
DB00279 | DB11348 | 1,152 | 1,065 | [
"DDInter1074",
"DDInter279"
] | Liothyronine | Calcium Phosphate | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1152,
24,
1065
]
],
[
[
1152,
23,
819
],
[
819,
24,
1065
]
],
[
[
1152,
24,
1436
],
[
1436,
24,
1065
]
],
[
[
1152,
62,
88
],
[
88,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],... | Liothyronine may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer an... |
DB08816 | DB11581 | 578 | 1,456 | [
"DDInter1802",
"DDInter1926"
] | Ticagrelor | Venetoclax | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
578,
25,
1456
]
],
[
[
578,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
578,
63,
536
],
[
536,
24,
1456
]
],
[
[
578,
24,
241
],
[
241,
... | [
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbit... |
DB12141 | DB15822 | 971 | 69 | [
"DDInter817",
"DDInter1504"
] | Gilteritinib | Pralsetinib | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
971,
24,
69
]
],
[
[
971,
24,
283
],
[
283,
24,
69
]
],
[
[
971,
63,
1446
],
[
1446,
24,
69
]
],
[
[
971,
64,
985
],
[
985,
24,
... | [
[
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and L... |
DB00333 | DB14724 | 576 | 48 | [
"DDInter1166",
"DDInter634"
] | Methadone | Emapalumab | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
576,
24,
48
]
],
[
[
576,
1,
494
],
[
494,
24,
48
]
],
[
[
576,
1,
494
],
[
494,
23,
126
],
[
126,
24,
48
]
],
[
[
576,
6,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moder... | Methadone (Compound) resembles Disopyramide (Compound) and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Methadone (Compound) resembles Disopyramide (Compound) and Disopyramide may cause a minor interaction that can limit clinical effects when taken with Warfari... |
DB00801 | DB01205 | 1,563 | 1,404 | [
"DDInter850",
"DDInter748"
] | Halazepam | Flumazenil | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. | Moderate | 1 | [
[
[
1563,
24,
1404
]
],
[
[
1563,
6,
13500
],
[
13500,
45,
1404
]
],
[
[
1563,
1,
902
],
[
902,
24,
1404
]
],
[
[
1563,
40,
1382
],
[
1382... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flumazenil"
]
],
[
[
"Halazepam",
"{u} (Compound) binds {v} (Gene)",
"GABRA5"
],
[
"GABRA5",
"{u} (Gene) is bound by {v} (Compound)",
... | Halazepam (Compound) binds GABRA5 (Gene) and GABRA5 (Gene) is bound by Flumazenil (Compound)
Halazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Flumazenil
Halazepam (Compound) resembles Midazolam (Compound) and Midazolam may ca... |
DB00945 | DB01129 | 1,479 | 379 | [
"DDInter20",
"DDInter1559"
] | Acetylsalicylic acid | Rabeprazole | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Minor | 0 | [
[
[
1479,
23,
379
]
],
[
[
1479,
62,
1215
],
[
1215,
40,
379
]
],
[
[
1479,
62,
660
],
[
660,
1,
379
]
],
[
[
1479,
6,
10215
],
[
10215,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rabeprazole"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazo... | Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) resembl... |
DB01246 | DB09076 | 820 | 1,116 | [
"DDInter45",
"DDInter1899"
] | Alimemazine | Umeclidinium | A phenothiazine derivative that is used as an antipruritic. | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
820,
24,
1116
]
],
[
[
820,
24,
849
],
[
849,
24,
1116
]
],
[
[
820,
64,
1300
],
[
1300,
24,
1116
]
],
[
[
820,
63,
358
],
[
358,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Alimemazine may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol may ... |
DB00023 | DB00675 | 305 | 888 | [
"DDInter127",
"DDInter1744"
] | Asparaginase Escherichia coli | Tamoxifen | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
305,
24,
888
]
],
[
[
305,
24,
303
],
[
303,
23,
888
]
],
[
[
305,
24,
256
],
[
256,
62,
888
]
],
[
[
305,
24,
1627
],
[
1627,
6... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Tamoxifen
Asparaginase Escherichia coli may cause a moderate interaction... |
DB01064 | DB08868 | 1,148 | 1,011 | [
"DDInter987",
"DDInter737"
] | Isoprenaline | Fingolimod | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Moderate | 1 | [
[
[
1148,
24,
1011
]
],
[
[
1148,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1148,
24,
144
],
[
144,
63,
1011
]
],
[
[
1148,
63,
867
],
[
867... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side E... | Isoprenaline (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when take... |
DB00978 | DB13074 | 739 | 877 | [
"DDInter1084",
"DDInter1110"
] | Lomefloxacin | Macimorelin | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
739,
25,
877
]
],
[
[
739,
62,
112
],
[
112,
23,
877
]
],
[
[
739,
63,
1479
],
[
1479,
24,
877
]
],
[
[
739,
24,
913
],
[
913,
2... | [
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicyli... |
DB00557 | DB09076 | 252 | 1,116 | [
"DDInter895",
"DDInter1899"
] | Hydroxyzine | Umeclidinium | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
252,
24,
1116
]
],
[
[
252,
24,
849
],
[
849,
24,
1116
]
],
[
[
252,
63,
128
],
[
128,
24,
1116
]
],
[
[
252,
1,
623
],
[
623,
2... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramin... |
DB01267 | DB11186 | 519 | 1,609 | [
"DDInter1381",
"DDInter1427"
] | Paliperidone | Pentoxyverine | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
519,
24,
1609
]
],
[
[
519,
24,
649
],
[
649,
24,
1609
]
],
[
[
519,
63,
506
],
[
506,
24,
1609
]
],
[
[
519,
40,
1664
],
[
1664,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorph... |
DB00990 | DB12887 | 1,547 | 1,598 | [
"DDInter705",
"DDInter1750"
] | Exemestane | Tazemetostat | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1547,
24,
1598
]
],
[
[
1547,
24,
1476
],
[
1476,
24,
1598
]
],
[
[
1547,
63,
1324
],
[
1324,
24,
1598
]
],
[
[
1547,
1,
891
],
[
891,... | [
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Tr... |
DB00041 | DB00372 | 1,648 | 999 | [
"DDInter38",
"DDInter1793"
] | Aldesleukin | Thiethylperazine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
1648,
24,
999
]
],
[
[
1648,
24,
17
],
[
17,
63,
999
]
],
[
[
1648,
25,
695
],
[
695,
24,
999
]
],
[
[
1648,
24,
1023
],
[
1023,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Aldesleukin may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause ... |
DB00986 | DB08815 | 1,192 | 154 | [
"DDInter834",
"DDInter1104"
] | Glycopyrronium | Lurasidone | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1192,
24,
154
]
],
[
[
1192,
21,
29118
],
[
29118,
60,
154
]
],
[
[
1192,
63,
100
],
[
100,
24,
154
]
],
[
[
1192,
24,
401
],
[
401,
... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Glycopyrronium",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Eff... | Glycopyrronium (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Lurasidone (Compound)
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases w... |
DB00018 | DB00277 | 199 | 1,031 | [
"DDInter945",
"DDInter1791"
] | Interferon alfa-n3 | Theophylline | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
199,
24,
1031
]
],
[
[
199,
24,
1383
],
[
1383,
63,
1031
]
],
[
[
199,
25,
593
],
[
593,
64,
1031
]
],
[
[
199,
24,
1383
],
[
1383,
... | [
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium su... | Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Bupropion ... |
DB00556 | DB01259 | 1,262 | 392 | [
"DDInter1429",
"DDInter1024"
] | Perflutren | Lapatinib | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1262,
24,
392
]
],
[
[
1262,
21,
28852
],
[
28852,
60,
392
]
],
[
[
1262,
23,
112
],
[
112,
23,
392
]
],
[
[
1262,
24,
918
],
[
918,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is cau... | Perflutren (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapa... |
DB00860 | DB04865 | 891 | 4 | [
"DDInter1513",
"DDInter1335"
] | Prednisolone | Omacetaxine mepesuccinate | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
891,
24,
4
]
],
[
[
891,
7,
3163
],
[
3163,
46,
4
]
],
[
[
891,
18,
4357
],
[
4357,
46,
4
]
],
[
[
891,
6,
1899
],
[
1899,
46,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Prednisolone",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) i... | Prednisolone (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Prednisolone (Compound) downregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Prednisolone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated... |
DB00422 | DB00907 | 895 | 290 | [
"DDInter1189",
"DDInter427"
] | Methylphenidate | Cocaine (topical) | Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cogni... | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Major | 2 | [
[
[
895,
25,
290
]
],
[
[
895,
1,
11473
],
[
11473,
1,
290
]
],
[
[
895,
40,
85
],
[
85,
1,
290
]
],
[
[
895,
6,
2437
],
[
2437,
45,... | [
[
[
"Methylphenidate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Methylphenidate",
"{u} (Compound) resembles {v} (Compound)",
"Hexylcaine"
],
[
"Hexylcaine",
"{u} (Compound) resembles {v} (C... | Methylphenidate may lead to a major life threatening interaction when taken with Cocaine
Methylphenidate (Compound) resembles Hexylcaine (Compound) and Hexylcaine (Compound) resembles Cocaine (Compound)
Methylphenidate (Compound) resembles Atropine (Compound) and Atropine (Compound) resembles Cocaine (Compound)
Methylp... |
DB00549 | DB00649 | 522 | 231 | [
"DDInter1955",
"DDInter1710"
] | Zafirlukast | Stavudine | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
522,
24,
231
]
],
[
[
522,
24,
1477
],
[
1477,
40,
231
]
],
[
[
522,
21,
29272
],
[
29272,
60,
231
]
],
[
[
522,
24,
375
],
[
375,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Stavudine (Compound)
Zafirlukast (Compound) causes Accidental injury (Side Effect) and Accidental injury (Side Effect) is caused by Stavudine (Compound)
Zafirlukast may cause a mo... |
DB01065 | DB01181 | 43 | 1,532 | [
"DDInter1142",
"DDInter906"
] | Melatonin | Ifosfamide | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice g... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
43,
24,
1532
]
],
[
[
43,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
43,
18,
8109
],
[
8109,
57,
1532
]
],
[
[
43,
21,
28956
],
[
28956,
... | [
[
[
"Melatonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Melatonin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Melatonin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Melatonin (Compound) downregulates NVL (Gene) and NVL (Gene) is downregulated by Ifosfamide (Compound)
Melatonin (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Mel... |
DB00106 | DB00889 | 618 | 1,133 | [
"DDInter4",
"DDInter840"
] | Abarelix | Granisetron | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
618,
24,
1133
]
],
[
[
618,
23,
112
],
[
112,
62,
1133
]
],
[
[
618,
24,
1213
],
[
1213,
63,
1133
]
],
[
[
618,
24,
1005
],
[
1005,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Granisetron
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatini... |
DB00852 | DB04398 | 1,445 | 193 | [
"DDInter1545",
"DDInter1015"
] | Pseudoephedrine | Lactic acid | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. It is produced by fermentation of a sugar source, such as ... | Moderate | 1 | [
[
[
1445,
24,
193
]
],
[
[
1445,
63,
590
],
[
590,
23,
193
]
],
[
[
1445,
24,
1411
],
[
1411,
23,
193
]
],
[
[
1445,
1,
22
],
[
22,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactic acid"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Tolbut... |
DB00078 | DB06228 | 1,172 | 792 | [
"DDInter898",
"DDInter1609"
] | Ibritumomab tiuxetan | Rivaroxaban | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
1172,
25,
792
]
],
[
[
1172,
23,
944
],
[
944,
62,
792
]
],
[
[
1172,
24,
1683
],
[
1683,
24,
792
]
],
[
[
1172,
63,
1184
],
[
1184,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[... | Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Rivaroxaban
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Usteki... |
DB00486 | DB00810 | 1,614 | 456 | [
"DDInter1253",
"DDInter211"
] | Nabilone | Biperiden | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Moderate | 1 | [
[
[
1614,
24,
456
]
],
[
[
1614,
63,
1105
],
[
1105,
40,
456
]
],
[
[
1614,
24,
104
],
[
104,
63,
456
]
],
[
[
1614,
24,
832
],
[
832,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Biperiden (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction t... |
DB04946 | DB05812 | 924 | 1,374 | [
"DDInter907",
"DDInter8"
] | Iloperidone | Abiraterone | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
924,
25,
1374
]
],
[
[
924,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
924,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
924,
62,
112
],
[
112,... | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Iloperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Abir... | Iloperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Iloperidone (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Iloperidone may cause a minor interaction that can limit clinical effects when taken with Metronidaz... |
DB00247 | DB12267 | 1,131 | 1,476 | [
"DDInter1194",
"DDInter233"
] | Methysergide | Brigatinib | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1131,
24,
1476
]
],
[
[
1131,
24,
951
],
[
951,
24,
1476
]
],
[
[
1131,
40,
628
],
[
628,
24,
1476
]
],
[
[
1131,
24,
982
],
[
982,
... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
... | Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Methysergide (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction th... |
DB00794 | DB06282 | 759 | 516 | [
"DDInter1521",
"DDInter1053"
] | Primidone | Levocetirizine | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
759,
24,
516
]
],
[
[
759,
63,
1031
],
[
1031,
23,
516
]
],
[
[
759,
63,
701
],
[
701,
24,
516
]
],
[
[
759,
1,
697
],
[
697,
24... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Cl... |
DB00467 | DB11093 | 1,467 | 636 | [
"DDInter644",
"DDInter273"
] | Enoxacin | Calcium citrate | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
1467,
24,
636
]
],
[
[
1467,
40,
739
],
[
739,
24,
636
]
],
[
[
1467,
1,
1539
],
[
1539,
24,
636
]
],
[
[
1467,
24,
115
],
[
115,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a mo... | Enoxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Enoxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium ... |
DB00968 | DB01168 | 1,551 | 1,053 | [
"DDInter1185",
"DDInter1526"
] | Methyldopa | Procarbazine | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1551,
25,
1053
]
],
[
[
1551,
18,
4930
],
[
4930,
57,
1053
]
],
[
[
1551,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1551,
24,
480
],
[
4... | [
[
[
"Methyldopa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Methyldopa",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Methyldopa (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Procarbazine (Compound)
Methyldopa (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Formote... |
DB00418 | DB00451 | 536 | 542 | [
"DDInter1650",
"DDInter1064"
] | Secobarbital | Levothyroxine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Moderate | 1 | [
[
[
536,
24,
542
]
],
[
[
536,
63,
1152
],
[
1152,
1,
542
]
],
[
[
536,
6,
3486
],
[
3486,
45,
542
]
],
[
[
536,
21,
28722
],
[
28722,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Levothyroxine (Compound)
Secobarbital (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Levothyroxine (Compound)
Secobarbital (Compound) causes Nausea (Side Effect) ... |
DB01246 | DB11632 | 820 | 580 | [
"DDInter45",
"DDInter1343"
] | Alimemazine | Opicapone | A phenothiazine derivative that is used as an antipruritic. | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
820,
24,
580
]
],
[
[
820,
1,
104
],
[
104,
24,
580
]
],
[
[
820,
40,
649
],
[
649,
24,
580
]
],
[
[
820,
63,
401
],
[
401,
24,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a mo... | Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Alimemazine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Opicap... |
DB01138 | DB05239 | 804 | 866 | [
"DDInter1726",
"DDInter425"
] | Sulfinpyrazone | Cobimetinib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
804,
24,
866
]
],
[
[
804,
24,
214
],
[
214,
63,
866
]
],
[
[
804,
63,
888
],
[
888,
24,
866
]
],
[
[
804,
62,
1101
],
[
1101,
2... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxife... |
DB00640 | DB00651 | 1,585 | 746 | [
"DDInter31",
"DDInter613"
] | Adenosine | Dyphylline | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Moderate | 1 | [
[
[
1585,
24,
746
]
],
[
[
1585,
63,
1031
],
[
1031,
1,
746
]
],
[
[
1585,
63,
1684
],
[
1684,
40,
746
]
],
[
[
1585,
6,
3691
],
[
3691,
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dyphylline"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline (Compound) resembles Dyphylline (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine (Compound) resembles Dyphylline (Compound)
Ad... |
DB01259 | DB11703 | 392 | 405 | [
"DDInter1024",
"DDInter9"
] | Lapatinib | Acalabrutinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
392,
24,
405
]
],
[
[
392,
63,
1051
],
[
1051,
24,
405
]
],
[
[
392,
24,
951
],
[
951,
24,
405
]
],
[
[
392,
25,
982
],
[
982,
6... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Palboc... |
DB01166 | DB08899 | 477 | 129 | [
"DDInter379",
"DDInter649"
] | Cilostazol | Enzalutamide | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
477,
24,
129
]
],
[
[
477,
63,
918
],
[
918,
1,
129
]
],
[
[
477,
6,
8374
],
[
8374,
45,
129
]
],
[
[
477,
21,
28703
],
[
28703,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Cilostazol (Compound) causes Pruritus (Side Effect) and Pr... |
DB00845 | DB05812 | 1,490 | 1,374 | [
"DDInter406",
"DDInter8"
] | Clofazimine | Abiraterone | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1490,
24,
1374
]
],
[
[
1490,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
1490,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1490,
23,
112
],
[
11... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofazimine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Clofazimine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Clofazimine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidaz... |
DB00562 | DB00618 | 1,014 | 1,572 | [
"DDInter188",
"DDInter498"
] | Benzthiazide | Demeclocycline | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Minor | 0 | [
[
[
1014,
23,
1572
]
],
[
[
1014,
23,
1620
],
[
1620,
1,
1572
]
],
[
[
1014,
62,
964
],
[
964,
1,
1572
]
],
[
[
1014,
23,
1669
],
[
1669,
... | [
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
... | Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline (Compound) resembles Demeclocycline (Compound)
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycli... |
DB00001 | DB00476 | 1,578 | 109 | [
"DDInter1037",
"DDInter608"
] | Lepirudin | Duloxetine | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
1578,
24,
109
]
],
[
[
1578,
24,
758
],
[
758,
1,
109
]
],
[
[
1578,
25,
1409
],
[
1409,
63,
109
]
],
[
[
1578,
25,
273
],
[
273,
... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
... | Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Lepirudin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases ... |
DB06616 | DB11627 | 594 | 1,367 | [
"DDInter224",
"DDInter860"
] | Bosutinib | Hepatitis B Vaccine (Recombinant) | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
594,
24,
1367
]
],
[
[
594,
63,
1560
],
[
1560,
24,
1367
]
],
[
[
594,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
594,
25,
375
],
[
375,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegasp... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bosutinib may lead to a major life threatening interaction when taken with Cladribine ... |
DB08870 | DB11718 | 850 | 927 | [
"DDInter228",
"DDInter640"
] | Brentuximab vedotin | Encorafenib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
850,
24,
927
]
],
[
[
850,
63,
112
],
[
112,
23,
927
]
],
[
[
850,
63,
495
],
[
495,
24,
927
]
],
[
[
850,
24,
1228
],
[
1228,
2... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronid... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken wit... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.